Checchi Capital Advisers LLC lessened its holdings in Allergan PLC. (NYSE:AGN) by 14.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,220 shares of the company’s stock after selling 375 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Allergan PLC. were worth $455,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in AGN. Howard Hughes Medical Institute bought a new stake in shares of Allergan PLC. in the second quarter valued at about $103,000. Cable Hill Partners LLC boosted its position in shares of Allergan PLC. by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares during the period. Rockefeller Financial Services Inc. boosted its position in shares of Allergan PLC. by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after acquiring an additional 400 shares during the period. Jacobi Capital Management LLC boosted its position in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after acquiring an additional 22 shares during the period. Finally, Massey Quick & Co. LLC boosted its position in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after acquiring an additional 385 shares during the period. 82.14% of the stock is owned by institutional investors.

Allergan PLC. (AGN) traded down $0.58 during trading on Tuesday, hitting $174.34. The stock had a trading volume of 3,753,928 shares, compared to its average volume of 4,510,000. Allergan PLC. has a one year low of $169.64 and a one year high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The firm has a market capitalization of $57,980.00, a P/E ratio of 11.34, a P/E/G ratio of 0.93 and a beta of 1.12.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the firm posted $3.32 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. equities research analysts predict that Allergan PLC. will post 16.27 EPS for the current fiscal year.

Allergan PLC. declared that its board has initiated a stock buyback plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.61%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is currently -12.39%.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley reduced their target price on shares of Allergan PLC. from $228.00 to $200.00 and set an “equal weight” rating for the company in a research report on Thursday, November 2nd. Cantor Fitzgerald reduced their target price on shares of Allergan PLC. to $191.00 and set a “neutral” rating for the company in a research report on Thursday, November 2nd. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $245.00 price target (down previously from $258.00) on shares of Allergan PLC. in a research note on Thursday, November 2nd. Royal Bank Of Canada dropped their price target on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. Finally, Zacks Investment Research raised Allergan PLC. from a “sell” rating to a “hold” rating in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $246.73.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/07/checchi-capital-advisers-llc-sells-375-shares-of-allergan-plc-agn.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.